0.5112
10.99%
-0.0657
前日終値:
$0.5769
開ける:
$0.58
24時間の取引高:
83,285
Relative Volume:
0.84
時価総額:
$10.11M
収益:
$9.15M
当期純損益:
$-16.18M
株価収益率:
-0.2905
EPS:
-1.76
ネットキャッシュフロー:
$-15.92M
1週間 パフォーマンス:
-26.64%
1か月 パフォーマンス:
-31.52%
6か月 パフォーマンス:
-68.30%
1年 パフォーマンス:
-89.52%
Aspira Womens Health Inc Stock (AWH) Company Profile
名前
Aspira Womens Health Inc
セクター
電話
512-519-0400
住所
12117 BEE CAVES ROAD BUILDING THREE, AUSTIN
AWH を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
AWH
Aspira Womens Health Inc
|
0.5112 | 10.11M | 9.15M | -16.18M | -15.92M | -1.76 |
TMO
Thermo Fisher Scientific Inc
|
558.29 | 213.05B | 42.37B | 6.14B | 7.78B | 15.95 |
DHR
Danaher Corp
|
240.40 | 171.63B | 23.74B | 3.89B | 4.98B | 5.24 |
A
Agilent Technologies Inc
|
145.77 | 40.96B | 6.51B | 1.29B | 1.37B | 4.42 |
IQV
Iqvia Holdings Inc
|
197.46 | 35.93B | 15.32B | 1.41B | 1.96B | 7.62 |
IDXX
Idexx Laboratories Inc
|
428.95 | 34.28B | 3.84B | 866.24M | 792.60M | 10.37 |
Aspira Womens Health Inc Stock (AWH) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2022-01-12 | 再開されました | Cantor Fitzgerald | Overweight |
2021-03-29 | 開始されました | Truist | Buy |
2021-01-29 | 開始されました | Cantor Fitzgerald | Overweight |
2020-10-30 | 開始されました | William Blair | Outperform |
Aspira Womens Health Inc (AWH) 最新ニュース
Bioxytran (OTCMKTS:BIXT) to Release Cancer Preprint Revealing Potential Immunotherapy EnhancementOn January 10, 2025, Bioxytran Inc., a clinical-stage biotechnology company focused on developing oral and intravenous drugs for various conditions, a - Defense World
Aspira Women’s Health (NASDAQ:AWH) Now Covered by Analysts at StockNews.com - Defense World
Aspira Women’s Health Appoints Mike Buhle as SVP of Commercial Operations - citybiz
Aspira Women's Health Inc. Appoints Mike Buhle as SVP of Commercial Operations - Marketscreener.com
Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations - AccessWire
Aspira Women's Health CFO resigns, CEO assumes duties - Investing.com
Aspira Women’s Health CFO Resignation and Leadership Update - TipRanks
AWH Stock Surges Over 5% Amid Mixed Analyst Ratings - GuruFocus.com
Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated at StockNews.com - Defense World
Aspira Women's Health in Shelton to use $10M grant to create blood test to detect endometriosis - CTPost
Aspira Women’s Health (NASDAQ:AWH) Earns Hold Rating from Analysts at StockNews.com - Defense World
Organon & Co. (NYSE: OGN) Reduces Board Size Following Resignation of Director - Defense World
Aspira Women's Health's SWOT analysis: stock outlook amid diagnostic growth - Investing.com Nigeria
Aspira Women's Health CEO steps down, interim appointed By Investing.com - Investing.com Canada
Aspira Women’s Health CEO Transition and Leadership Change - TipRanks
AWHAspira Women's Health Inc. Latest Stock News & Market Updates - StockTitan
Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer - citybiz
Aspira Women’s Health Appoints Dr. Sandra Milligan as Interim CEO - citybiz
Akari Therapeutics Strengthens Leadership: Former CFO Returns After $50M Fundraising Success - StockTitan
Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO - The Manila Times
Aspira Women's Health CEO Steps Down Following OvaWatch Launch, $10M Research Grant Success - StockTitan
StockNews.com Begins Coverage on Aspira Women’s Health (NASDAQ:AWH) - Defense World
Aspira Women's Health's SWOT analysis: stock faces growth potential amid financial hurdles - Investing.com Nigeria
CURE® SURVEY UNVEILS WHAT INVESTORS LOOK FOR IN FUNDING WOMEN'S HEALTH - PR Newswire
AWS supports ARPA-H Sprint for Women’s Health to advance crucial research and solutions - AWS Blog
Aspira Women's Health Successfully Reaches the First Milestone of the ARPA-H $10 Million Award - The Manila Times
Aspira Women's Health Secures $2M ARPA-H Grant for AI-Powered Endometriosis Test - StockTitan
StockNews.com Initiates Coverage on Aspira Women’s Health (NASDAQ:AWH) - Defense World
Aspira: Q3 Earnings Snapshot - New Haven Register
Aspira Women's Health Inc. (AWH) reports earnings - Quartzy
Aspira Women's Health Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Aspira Women’s Health Inc. (NASDAQ:AWH) Q3 2024 Earnings Call Transcript - MSN
Aspira Womens Health Inc (AWH) Q3 2024 Earnings Call Highlights: Strategic Wins Amidst Market ... - Yahoo Finance
Aspira Womens Health Inc (AWH) Q3 2024 Earnings Call Highlights: Strategic Wins Amidst Market ... By GuruFocus - Investing.com Canada
Aspira Women’s Health Reports Q3 2024 Growth and Strategic Advances - TipRanks
ARMISTICE CAPITAL, LLC Expands Stake in Aspira Womens Health Inc - GuruFocus.com
Aspira Women’s Health reports Q3 revenue $2.3M, consensus $2.73M - TipRanks
Aspira Women's Health Reports Selected Third Quarter 2024 Financial Results - The Manila Times
Aspira Women's Health Q3: OvaWatch Grows 27%, Secures $10M Federal Contract | AWH Stock News - StockTitan
Aspira Women's Health Inc (AWH) Q3 2024 Earnings Report Preview: What to Expect - GuruFocus.com
Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated by Analysts at StockNews.com - Defense World
Aspira Women?s Health Expands Co-Marketing and Distribution Collaboration with BioReference to Include OvaWatch - Marketscreener.com
Aspira Women's Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch® - The Manila Times
Aspira Women's Health Expands BioReference Partnership, Reaches 15M+ Women With OvaWatch | AWH Stock News - StockTitan
FDA's LDT RULE: Steps to Prepare for Your FDA 1st Milestone SubmissionDARKDaily.com - DARKDaily.com - Laboratory News
Aspira Womens Health Inc (AWH) 財務データ
収益
当期純利益
現金流量
EPS
Aspira Womens Health Inc (AWH) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Fralick Celeste Rachelle | Director |
Dec 31 '24 |
Option Exercise |
0.00 |
5,000 |
0 |
50,665 |
Parnell Winfred | Director |
Dec 31 '24 |
Option Exercise |
0.00 |
5,157 |
0 |
60,897 |
Cavanaugh Stefanie L. | Director |
Dec 31 '24 |
Option Exercise |
0.00 |
5,937 |
0 |
66,851 |
Ragard John Phillip | Director |
Dec 31 '24 |
Option Exercise |
0.00 |
4,844 |
0 |
125,047 |
Milligan Sandra | Interim CEO & President |
Dec 31 '24 |
Option Exercise |
0.00 |
20,000 |
0 |
20,000 |
Vos Ellen O'Connor | Director |
Dec 31 '24 |
Option Exercise |
0.00 |
5,312 |
0 |
63,364 |
Vos Ellen O'Connor | Director |
Sep 30 '24 |
Option Exercise |
0.00 |
5,313 |
0 |
58,052 |
Cavanaugh Stefanie L. | Director |
Sep 30 '24 |
Option Exercise |
0.00 |
5,938 |
0 |
60,914 |
Parnell Winfred | Director |
Sep 30 '24 |
Option Exercise |
0.00 |
5,156 |
0 |
55,740 |
Herchuk Jannie Prestridge | Director |
Sep 30 '24 |
Option Exercise |
0.00 |
8,438 |
0 |
57,190 |
大文字化:
|
ボリューム (24 時間):